Morin (C5297): Mechanism, Evidence, and Applications as a Natural Flavonoid Antioxidant

Executive Summary: Morin (2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one) is a natural flavonoid antioxidant isolated from Maclura pomifera and available as a high-purity reagent (C5297) from APExBIO. It acts as a potent inhibitor of adenosine 5′-monophosphate deaminase (AMPD), restoring mitochondrial energy metabolism in models of high-fructose-induced podocyte injury (Yang et al. 2025). Morin is soluble in DMSO (≥19.53 mg/mL) and ethanol (≥6.04 mg/mL), but insoluble in water, and serves as a fluorescent probe for aluminum ion detection (APExBIO). Its efficacy is validated by HPLC, MS, and NMR (≥96.81% purity), supporting research in diabetes, cancer, and neurodegenerative disease models. The product’s biochemical and workflow parameters are established for reproducibility and translational relevance.

Biological Rationale

Morin is a polyphenolic flavonoid with the IUPAC name 2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one and a molecular weight of 302.24 Da (APExBIO). It is sourced from Maclura pomifera and related plant species. Natural flavonoids, including Morin, are recognized for their antioxidant, anti-inflammatory, cardioprotective, neuroprotective, anti-diabetic, and antimicrobial activities (plx4720.com). Morin’s relevance in disease models is based on its ability to modulate cellular energy metabolism and oxidative stress, two key drivers in the pathogenesis of diabetes, cancer, and neurodegenerative disorders. Disruption of mitochondrial function, particularly in podocytes (specialized kidney cells), is a hallmark of diabetic nephropathy and other progressive kidney diseases (Yang et al. 2025).

Mechanism of Action of Morin

Morin directly inhibits adenosine 5′-monophosphate deaminase (AMPD), a key enzyme in the purine nucleotide cycle (PNC). AMPD catalyzes the deamination of AMP to IMP, modulating both ATP homeostasis and mitochondrial function. Under conditions of high fructose exposure, AMPD activity in podocytes increases, leading to ATP depletion and impaired mitochondrial respiration. Morin binds selectively to AMPD2, suppressing its activity, as confirmed by molecular docking and siRNA knockdown studies (Yang et al. 2025). This inhibition restores basal oxygen consumption rate (OCR), ATP synthesis, and maximal mitochondrial respiration. Additionally, Morin acts as a fluorescent chelator for Al³⁺ ions, enabling its use as a biochemical probe (anti-inflammatory-peptide-1.com).

Evidence & Benchmarks

• Morin (C5297) inhibits AMPD activity in high-fructose-exposed podocytes, reducing enzyme activity by >60% at 10 μM in vitro (Yang et al. 2025).
• Morin administration (20 mg/kg/day, oral, 4 weeks) in rats fed a high-fructose diet improves podocyte ultrastructure and decreases urinary albumin-to-creatinine ratio (UACR) by ~45% (Yang et al. 2025).
• Morin restores mitochondrial respiration rates (OCR) in mouse podocyte clone-5 (MPC5) cells exposed to 5 mM fructose, with maximal respiration increased by 38% compared to untreated controls (Yang et al. 2025).
• Morin (≥96.81% purity by HPLC/MS/NMR) is stable at -20°C for up to 24 months if protected from light and moisture (APExBIO).
• Morin’s fluorescence increases >10-fold in the presence of 10 μM Al³⁺ ions in neutral aqueous buffer, supporting its use as an aluminum sensor (anti-inflammatory-peptide-1.com).
• Morin is insoluble in water but dissolves in DMSO (≥19.53 mg/mL) and ethanol (≥6.04 mg/mL) at room temperature (APExBIO).

This article extends prior reviews (e.g., Morin: Bridging Mechanistic Insights) by providing direct quantitative benchmarks and clarifying AMPD-centric mechanisms in podocyte injury models.

Applications, Limits & Misconceptions

Morin is validated for use in in vitro and in vivo research on diabetes, kidney disease, cancer, and neurodegenerative disorders. It is also employed as a selective fluorescent probe for Al³⁺ quantification in biological samples. Its application is supported by reproducible analytical verification (HPLC, MS, NMR) and established solubility/stability profiles for experimental workflows (Morin C5297 kit).

Common Pitfalls or Misconceptions

• Morin is not water soluble; direct dissolution in aqueous media leads to precipitation and unreliable dosing.
• Morin’s AMPD inhibition is validated primarily in podocyte and kidney cell models; effects in non-renal tissues may differ and require independent confirmation.
• Antioxidant and bioactive effects are dose- and cell-type specific; exceeding recommended working concentrations may induce off-target toxicity.
• Morin’s fluorescence for Al³⁺ detection is sensitive to pH and competing chelators; not all metal ions yield the same signal response.
• Long-term solution stability is limited; stock solutions in DMSO or ethanol should be freshly prepared for each experiment.

For detailed application protocols and troubleshooting, see Morin (C5297): Scenario-Driven Solutions for Cell Viability, which this article updates with expanded AMPD mechanistic data.

Workflow Integration & Parameters

Morin (C5297, APExBIO) is supplied as a high-purity powder for research use. For in vitro assays, prepare stock solutions in DMSO (≥19.53 mg/mL) or ethanol (≥6.04 mg/mL), filter-sterilize, and dilute into working concentrations immediately before use. Store solid at -20°C, protected from light and moisture. For in vivo studies, dissolve Morin in appropriate vehicle (e.g., DMSO:saline), ensuring full solubilization. Analytical verification (HPLC, MS, NMR) is provided with each batch (≥96.81% purity).

Morin integrates into cellular, biochemical, and animal model workflows targeting mitochondrial dysfunction, oxidative stress, and purine metabolism. For translational and advanced disease models, see contrasting utility with other probes in Morin: Natural Flavonoid Antioxidant for Advanced Disease Models; this article clarifies AMPD-targeted mechanisms and workflow reproducibility.

Conclusion & Outlook

Morin (C5297) is a rigorously characterized natural flavonoid antioxidant with validated utility for modulating mitochondrial energy metabolism via AMPD inhibition. It is distinguished by its purity, solubility profile, and dual function as a fluorescent probe. Current evidence supports its use in diabetes, kidney disease, cancer, and neurodegenerative research. Future studies may expand Morin’s utility to new disease models and therapeutic strategies, contingent on further mechanistic and translational validation (Yang et al. 2025).